|
|
|
|
Vol. 16, Issue 8, 3632-3641, August 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



* Department of Histology and Medical Embryology, University of Rome "La Sapienza," 00161 Roma, Italy;
Interuniversity Institute of Myology, University of Rome "La Sapienza," 00161 Roma, Italy; and
Mouse Biology Programme, European Molecular Biology Laboratory, 00016 Monterotondo, Italy
Submitted January 21, 2005;
Revised May 11, 2005;
Accepted May 24, 2005
Monitoring Editor: Marianne Bronner-Fraser
Arg8-vasopressin (AVP) promotes the differentiation of myogenic cell lines and mouse primary satellite cells by mechanisms involving the transcriptional activation of myogenic bHLH regulatory factors and myocyte enhancer factor 2 (MEF2). We here report that AVP treatment of L6 cells results in the activation of calcineurin-dependent differentiation, increased expression of MEF2 and GATA2, and nuclear translocation of the calcineurin target NFATc1. Interaction of these three factors occurs at MEF2 sites of muscle specific genes. The different kinetics of AVP-dependent expression of early (myogenin) and late (MCK) muscle-specific genes correlate with different acetylation levels of histones at their MEF2 sites. The cooperative role of calcineurin and Ca2+/calmodulin-dependent kinase (CaMK) in AVP-dependent differentiation is demonstrated by the effect of inhibitors of the two pathways. We show here, for the first time, that AVP, a "novel" myogenesis promoting factor, activates both the calcineurin and the CaMK pathways, whose combined activation leads to the formation of multifactor complexes and is required for the full expression of the differentiated phenotype. Although MEF2NFATc1 complexes appear to regulate the expression of an early muscle-specific gene product (myogenin), the activation of late muscle-specific gene expression (MCK) involves the formation of complexes including GATA2.
Abbreviations used: AVP, arg8-vasopressin; CaMK, calcium/calmodulin-dependent kinase; CSA, cyclosporin A; HDAC, histone deacetylase; MCK, muscle creatine kinase; MEF2, myocyte enhancer factor 2; MHC, myosin heavy chain; NFAT, nuclear factor of activated T-cells.
Address correspondence to: Sergio Adamo (sergio.adamo{at}uniroma1.it).
This article has been cited by other articles:
![]() |
J. A. H. Smith, T. A. Kohn, A. K. Chetty, and E. O. Ojuka CaMK activation during exercise is required for histone hyperacetylation and MEF2A binding at the MEF2 site on the Glut4 gene Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E698 - E704. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Stupka, J. D. Schertzer, R. Bassel-Duby, E. N. Olson, and G. S. Lynch Stimulation of calcineurin A{alpha} activity attenuates muscle pathophysiology in mdx dystrophic mice Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R983 - R992. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gutkowska, M. Miszkurka, B. Danalache, N. Gassanov, D. Wang, and M. Jankowski Functional arginine vasopressin system in early heart maturation Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2262 - H2270. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gassanov, M. Jankowski, B. Danalache, D. Wang, R. Grygorczyk, U. C. Hoppe, and J. Gutkowska Arginine Vasopressin-mediated Cardiac Differentiation: INSIGHTS INTO THE ROLE OF ITS RECEPTORS AND NITRIC OXIDE SIGNALING J. Biol. Chem., April 13, 2007; 282(15): 11255 - 11265. [Abstract] [Full Text] [PDF] |
||||